AbbVie Highlights Long-Term Safety And Efficacy Of Fixed-Duration Venetoclax-Obinutuzumab In CLL14 Trial After 9.2-Year Follow-Up

Benzinga Newsdesk www.benzinga.com Positive 93.8%